Area of research
Computational Theory and Mathematics · Oncology
Research interest
Research focused on Protease and Lipotoxicity, with related work in Kinome, Cancer research, Enzyme. Notable publications include 'Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination', 'LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer', and 'Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M pro and Papain-like Protease PL pro of SARS-CoV-2'.
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer
Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and Its Variants Displaying Potent Antiviral Activity
Uncovering α-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies
A twist in the tale: shifting from covalent targeting of a tyrosine in JAK3 to a lysine in MK2
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma
Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-<i>b</i>]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities
Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination
Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M <sup>pro</sup> and Papain-like Protease PL <sup>pro</sup> of SARS-CoV-2
Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer